IN8BIO, INC.
INABNasdaq
$1.33
↓ -3.6%Jul 17 close · end-of-day
Price
1Y↓ -39.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$25.9M
Enterprise Value
$25.9M
P/E
—
P/S
—
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$19.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-83.3%
ROIC
-65.8%
Debt / Equity
—
Net Cash
—
Return 1Y
-39.6%
Company profile
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, which is in Phase I clinical trial for glioblastoma and solid tumors. InB-100, an allogeneic product candidate, is in clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.
- CEO
- William T. Ho
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- New York
- Website
- in8bio.com
Management & directors
- Ho William Tai-WeiPRESIDENT AND CEO
- Mccall PatrickCHIEF FINANCIAL OFFICER
- Rochlin KateChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
INAB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.26↓ -88.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.6M | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| Net income | -$8.6M | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| Diluted EPS | — | -$1.47 | -$1.36 | -$1.00 | -$17.05 | -$4.44 |
| Operating cash flow | -$7.1M | -$13.5M | -$24.1M | -$23.3M | -$24.1M | -$12.7M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.6M | -$7.1M | -$6.2M | -$5.5M | -$5.1M | -$3.9M | -$4.9M | -$5.1M |
| Net income | -$8.6M | -$7.1M | -$6.2M | -$5.5M | -$5.1M | -$3.9M | -$4.9M | -$5.1M |
| Diluted EPS | -$5.51 | -$4.49 | -$6.85 | -$2.16 | -$1.24 | -$0.85 | -$0.19 | -$0.26 |
| Operating cash flow | -$6.1M | -$6.1M | -$4.0M | -$3.1M | -$3.9M | -$3.5M | -$2.1M | -$4.9M |
| Free cash flow | -$6.1M | -$6.1M | — | -$3.1M | -$3.9M | -$3.5M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-27 | FAIRBAIRN EMILY | Gift | 724,637 | $0.00 | $0.00 | filing |
| 2025-12-22 | FAIRBAIRN EMILY | Award | 724,637 | $1.38 | $999,999.06 | filing |
| 2025-12-22 | Brandt Peter C. | Award | 72,464 | $1.38 | $100,000.32 | filing |
| 2025-12-22 | Ho William Tai-Wei· PRESIDENT AND CEO | Award | 36,232 | $1.38 | $50,000.16 | filing |
| 2025-12-22 | Roemer Alan S. | Award | 36,232 | $1.38 | $50,000.16 | filing |
| 2025-12-22 | McCall Patrick· CHIEF FINANCIAL OFFICER | Award | 7,247 | $1.38 | $10,000.86 | filing |
| 2025-12-22 | Rochlin Kate· Chief Operating Officer | Award | 7,247 | $1.38 | $10,000.86 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.